S&P 500   3,002.66 (+1.23%)
DOW   27,087.44 (+1.12%)
QQQ   193.95 (+1.50%)
AAPL   235.81 (-0.03%)
FB   189.69 (+3.50%)
MSFT   141.57 (+1.45%)
GOOGL   1,245.75 (+2.30%)
AMZN   1,774.87 (+2.21%)
NVDA   197.72 (+6.00%)
MU   46.47 (+3.59%)
BABA   175.42 (+2.49%)
TSLA   259.00 (+0.79%)
AMD   30.89 (+1.18%)
F   9.08 (+2.83%)
ACB   3.81 (+8.56%)
BAC   29.99 (+2.92%)
GILD   65.55 (+1.61%)
DIS   130.26 (+0.43%)
S&P 500   3,002.66 (+1.23%)
DOW   27,087.44 (+1.12%)
QQQ   193.95 (+1.50%)
AAPL   235.81 (-0.03%)
FB   189.69 (+3.50%)
MSFT   141.57 (+1.45%)
GOOGL   1,245.75 (+2.30%)
AMZN   1,774.87 (+2.21%)
NVDA   197.72 (+6.00%)
MU   46.47 (+3.59%)
BABA   175.42 (+2.49%)
TSLA   259.00 (+0.79%)
AMD   30.89 (+1.18%)
F   9.08 (+2.83%)
ACB   3.81 (+8.56%)
BAC   29.99 (+2.92%)
GILD   65.55 (+1.61%)
DIS   130.26 (+0.43%)
Log in

Atossa Genetics Stock Price, News & Analysis (NASDAQ:ATOS)

$1.76
+0.09 (+5.39 %)
(As of 10/15/2019 02:25 PM ET)
Today's Range
$1.69
Now: $1.76
$2.05
50-Day Range
$1.69
MA: $1.96
$2.18
52-Week Range
$0.80
Now: $1.76
$7.39
Volume743,082 shs
Average Volume104,323 shs
Market Capitalization$16.07 million
P/E RatioN/A
Dividend YieldN/A
Beta3.23
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATOS
CUSIPN/A
Phone206-325-6086

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.10 per share

Profitability

Net Income$-11,400,000.00

Miscellaneous

Employees4
Market Cap$16.07 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive ATOS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.


Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions

What is Atossa Genetics' stock symbol?

Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."

When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work?

Atossa Genetics's stock reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split.

How were Atossa Genetics' earnings last quarter?

Atossa Genetics Inc (NASDAQ:ATOS) announced its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.32. View Atossa Genetics' Earnings History.

When is Atossa Genetics' next earnings date?

Atossa Genetics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Atossa Genetics.

What price target have analysts set for ATOS?

1 equities research analysts have issued twelve-month price targets for Atossa Genetics' shares. Their forecasts range from $9.00 to $9.00. On average, they expect Atossa Genetics' share price to reach $9.00 in the next year. This suggests a possible upside of 411.4% from the stock's current price. View Analyst Price Targets for Atossa Genetics.

What is the consensus analysts' recommendation for Atossa Genetics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Genetics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Atossa Genetics.

Has Atossa Genetics been receiving favorable news coverage?

News headlines about ATOS stock have been trending neutral this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Atossa Genetics earned a daily sentiment score of 0.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Atossa Genetics.

Are investors shorting Atossa Genetics?

Atossa Genetics saw a drop in short interest in September. As of September 30th, there was short interest totalling 221,200 shares, a drop of 19.2% from the August 30th total of 273,800 shares. Based on an average daily trading volume, of 135,400 shares, the short-interest ratio is presently 1.6 days. Approximately 2.4% of the shares of the company are sold short. View Atossa Genetics' Current Options Chain.

Who are some of Atossa Genetics' key competitors?

What other stocks do shareholders of Atossa Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Genetics investors own include Alibaba Group (BABA), Biopharmx (BPMX), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX), Synergy Pharmaceuticals (SGYP), NVIDIA (NVDA), Gevo (GEVO), Biocept (BIOC), Cara Therapeutics (CARA) and MannKind (MNKD).

Who are Atossa Genetics' key executives?

Atossa Genetics' management team includes the folowing people:
  • Dr. Steven C. Quay, Chairman, CEO & Pres (Age 68)
  • Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 55)
  • Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical Affairs
  • Dr. Jack Cuzick, Member of Scientific Advisory Board

How do I buy shares of Atossa Genetics?

Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Atossa Genetics' stock price today?

One share of ATOS stock can currently be purchased for approximately $1.76.

How big of a company is Atossa Genetics?

Atossa Genetics has a market capitalization of $16.07 million. The company earns $-11,400,000.00 in net income (profit) each year or ($5.50) on an earnings per share basis. Atossa Genetics employs 4 workers across the globe.View Additional Information About Atossa Genetics.

What is Atossa Genetics' official website?

The official website for Atossa Genetics is http://www.atossagenetics.com/.

How can I contact Atossa Genetics?

Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected]


MarketBeat Community Rating for Atossa Genetics (NASDAQ ATOS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  153 (Thanks for Voting!)
Underperform Votes:  179 (Thanks for Voting!)
Total Votes:  332
MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe ATOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel